These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22515438)

  • 1. Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial.
    Mathisen MS; Ravandi F
    Future Oncol; 2012 Apr; 8(4):351-7. PubMed ID: 22515438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
    Löwenberg B; Morgan G; Ossenkoppele GJ; Burnett AK; Zachée P; Dührsen U; Dierickx D; Müller-Tidow C; Sonneveld P; Krug U; Bone E; Flores N; Richardson AF; Hooftman L; Jenkins C; Zweegman S; Davies F
    J Clin Oncol; 2010 Oct; 28(28):4333-8. PubMed ID: 20733120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.
    DiNardo CD; Cortes JE
    Expert Opin Investig Drugs; 2014 Feb; 23(2):265-72. PubMed ID: 24313331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Dennis M; Burnett A; Hills R; Thomas I; Ariti C; Severinsen MT; Hemmaway C; Greaves P; Clark RE; Copland M; Russell N;
    Br J Haematol; 2021 Jul; 194(2):298-308. PubMed ID: 33961292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.
    Cortes J; Feldman E; Yee K; Rizzieri D; Advani AS; Charman A; Spruyt R; Toal M; Kantarjian H
    Lancet Oncol; 2013 Apr; 14(4):354-62. PubMed ID: 23453583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
    Jenkins C; Hewamana S; Krige D; Pepper C; Burnett A
    Leuk Res; 2011 May; 35(5):677-81. PubMed ID: 21145592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
    Mawad R; Becker PS; Hendrie P; Scott B; Wood BL; Dean C; Sandhu V; Deeg HJ; Walter R; Wang L; Myint H; Singer JW; Estey E; Pagel JM
    Br J Haematol; 2016 Jan; 172(2):238-45. PubMed ID: 26568032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
    van Herpen CM; Eskens FA; de Jonge M; Desar I; Hooftman L; Bone EA; Timmer-Bonte JN; Verweij J
    Br J Cancer; 2010 Oct; 103(9):1362-8. PubMed ID: 20877350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
    Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
    Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
    Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
    Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.
    Roboz GJ; Rosenblat T; Arellano M; Gobbi M; Altman JK; Montesinos P; O'Connell C; Solomon SR; Pigneux A; Vey N; Hills R; Jacobsen TF; Gianella-Borradori A; Foss Ø; Vetrhusand S; Giles FJ
    J Clin Oncol; 2014 Jun; 32(18):1919-26. PubMed ID: 24841975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
    Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
    Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
    Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; Espinoza-Delgado I; Ross DD
    Clin Cancer Res; 2013 Apr; 19(7):1838-51. PubMed ID: 23403629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Griffiths EA; Carraway HE; Chandhok NS; Prebet T
    Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.
    Ocio EM; Herrera P; Olave MT; Castro N; Pérez-Simón JA; Brunet S; Oriol A; Mateo M; Sanz MÁ; López J; Montesinos P; Chillón MC; Prieto-Conde MI; Díez-Campelo M; González M; Vidriales MB; Mateos MV; San Miguel JF;
    Haematologica; 2015 Oct; 100(10):1294-300. PubMed ID: 26160880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
    Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
    DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
    Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat for the treatment of acute myelogenous leukemia.
    Morabito F; Voso MT; Hohaus S; Gentile M; Vigna E; Recchia AG; Iovino L; Benedetti E; Lo-Coco F; Galimberti S
    Expert Opin Investig Drugs; 2016 Sep; 25(9):1117-31. PubMed ID: 27485472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.